

UBRELVY[®]
(ubrogepant) tablets 50mg
100mg



As of 04/22,^{1,2}

16 COUNT IS AVAILABLE FOR YOUR UBRELVY[®] PATIENTS

16^{100 mg} PACK



PRESCRIPTION

Name _____ DOB _____
Address _____ Date _____

R_x

**UBRELVY 100 mg
#16**

**TAKE ONE TABLET PRN
FOR MIGRAINE**

11 Refills

Signature _____

Prepare patients for unpredictable migraine attacks³

UBRELVY 100 mg tablets are available in a 16-count package, allowing your UBRELVY patients to have pills on hand when they need them most.

Eligible patients may pay as little as **\$0—ALL PILLS, ALL FILLS.***

UBRELVY is available in 50 mg and 100 mg tablets¹

- Taken orally, with or without food¹
- Take 50 mg or 100 mg to treat a migraine attack¹
- A second dose can be taken at least 2 hours after the initial dose, if needed¹
- The maximum daily dose is 200 mg¹
- Safety established in up to 8 migraines in a 30-day period¹

*Patient out-of-pocket costs may vary. This offer is only valid for commercially insured patients. Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. Please see full Program Terms, Conditions, and Eligibility Criteria available at UBRELVY.com/savings-terms.

INDICATION

UBRELVY[®] (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.

IMPORTANT SAFETY INFORMATION

Contraindication: Concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

Adverse Reactions: The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).

Please see full [Prescribing Information](#), or visit rxabbvie.com/pdf/ubrelvy_pi.pdf.

Dosing considerations:

- UBRELVY[®] should not be used concomitantly with strong CYP3A4 inhibitors, such as ketoconazole, itraconazole, or clarithromycin, as they will cause an increase in UBRELVY exposure¹
- Strong CYP3A4 inducers should be avoided as concomitant use will result in reduction of UBRELVY exposure¹
- Patients on moderate or weak CYP3A4 inhibitors or inducers or BCRP and/or P-gp only inhibitors will require dose modifications. See Section 2.2 of the Prescribing Information¹
- Avoid use in patients with end-stage renal disease¹
- Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors including cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, and with grapefruit juice; avoid second dose within 24 hours¹
- Severe hepatic or severe renal impairment: recommended dose is 50 mg; if needed, a second 50 mg dose may be taken at least 2 hours after the initial dose¹
- In clinical trials, patients were able to use concomitant preventive medications including topiramate, onabotulinumtoxinA, propranolol, and amitriptyline.⁴ None of these patients were on concomitant preventive medications that act on the CGRP pathway¹

Please see full [Prescribing Information](#), or visit rxabbvie.com/pdf/ubrelvy_pi.pdf.

References: 1. UBRELVY. Package insert. Allergan USA, Inc.; 2021. 2. Retail monthly prescription data from IQVIA on a 6-month rolling basis as of 04/22. 3. Serrano D, Lipton RB, Scher AI, et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. *J Headache Pain.* 2017;18:101. 4. Blumenfeld AM, Knievel K, Adams AM, et al. Ubrogepant is safe and efficacious in participants taking concomitant preventive medication for migraine: a pooled analysis of phase 3 trials. *Adv Ther.* 2022;39(1):692-705.